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Managing
anxiety disorders
in adults
GREGORY WILKINS BMed(Hons), FRANZCP; GAVIN ANDREWS MD, FRCPsych, FRANZCP
CAROLINE BELL BM BCh, MA, MRCPsych, MD
PHILIP BOYCE MB BS, MD, FRANZCP; CHRISTOPHER GALE MB BS, MD, FRANZCP
RONALD RAPEE PhD(Psychology), MS(Psychology), BS(Psychology)
LISA LAMPE MB BS, PhD, FRANZCP

The GP has a key role in identifying patients presenting with
anxiety symptoms and ensuring appropriate acute and long-term
management. There are two key messages for GPs to follow: once
you have made a diagnosis of an anxiety disorder, tell the patient
you have a treatment for it. Second, do not let your anxiety lead you
to prescribe inappropriately or overinvestigate for all possible
differential diagnoses.

A

nxiety disorders, like all mental
disorders, lie on a spectrum that
extends from normal anxiety to
transient symptoms, through to
severe and disabling symptoms that can
persist for years. The specific thoughts
and behaviours that characterise each of
the anxiety disorders are covered in the
RANZCP Clinical Practice Guidelines for
anxiety disorder.1 These disorders include

variants of excessive worry, acute attacks
of anxiety or panic and avoidance of
anxiety-provoking situations.
Panic disorder, social anxiety disorder
(SAD) and generalised anxiety disorder
(GAD) are the most common anxiety
disorders in Australia and New Zealand.
Obsessive compulsive disorder (OCD) and
post-traumatic stress disorder (PTSD)
have been moved out of the DSM-5 chapter
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on anxiety disorders and placed in their
own categories of ‘Obsessive compulsive
and related disorders’, and ‘Trauma and
stressor-related disorders’, respectively.
The systematic implementation of
anxiety disorder guidelines has been
shown to result in earlier treatment gains
and shorter treatment times.2 This article
draws from the RANZCP guidelines to
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KEY POINTS
• Management of anxiety disorder
•

•

•

•

•

requires a biopsychosocial and
lifestyle approach.
Anxiety disorders are common
and often disabling but are underrecognised and often poorly
treated in clinical practice.
Effective first-line treatments are
cognitive behavioural therapy
(CBT), either face-to-face or
digitally delivered (dCBT), and the
serotonergic antidepressants.
No matter what treatment is
selected, it is likely to take four to
six weeks to begin to show an
effect.
Functional recovery is the goal
and is achievable through
effective use of evidence-based
treatments.
Use of evidence-based clinical
practice guidelines for treatment
has been shown to result in better
outcomes.

© RAPIDEYE/ISTOCKPHOTO.COM
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is better, and the experience of practitioners is wider than with other classes
of medication, especially the older, or
first generation, antidepressants.

focus on the use of psychological treatments and pharmacotherapy to treat
panic disorder, SAD and GAD, for which
there is considerable evidence of efficacy.
The key features of these anxiety disorders
are presented in Table 1. This article also
provides practical clinical guidance on
cognitive behavioural therapy (CBT) as
the principal psychological treatment for

the anxiety disorders as it has the most
extensive evidence base for its efficacy.
Furthermore, it is available online, allowing easy and extensive dissemination. The
selective serotonin reuptake inhibitor
(SSRI) and serotonin and noradrenaline
reuptake inhibitor (SNRI) antidepressants
are also covered because the evidence base
of benefit is larger, the side effect profile

Factors contributing to the
onset of anxiety disorders
Anxiety disorders arise from a combination
of vulnerable personality traits, early life
stressors and psychosocial adversity (for
example, lack of support, hardship, dysfunctional relationships) and are often
triggered by stressful significant life events
(such as the death of a loved one, an illness,
childbirth or workplace bullying). Temperamental traits, with a moderate level of
heritability (such as neuroticism or negative
emotionality), are important vulnerability
factors for anxiety; neuroticism, in particular, seems to confer greater vulnerability to
how an individual responds to psychological distress, which may precipitate an
anxiety disorder in the context of environmental or interpersonal stressors.
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Managing anxiety disorders in adults continued

TABLE 1. KEY FEATURES OF SPECIFIC ANXIETY DISORDERS
Panic disorder

Sudden attacks of fear or anxiety (usually brief, but which may be so
severe that the person thinks they might collapse or die), concern
about the attacks recurring, and avoidance of or marked distress in
situations in which they might recur.

Social anxiety
disorder
(SAD)

Fear and avoidance of situations where the person thinks they might
be the centre of attention; concern about doing or saying something
embarrassing, and that others might notice the anxiety and be critical.

Generalised
anxiety
disorder
(GAD)

Months of excessive worry over everyday things, avoiding or seeking
reassurance about situations when the outcome is uncertain, and
being overly concerned about things that could go wrong. Worry is
experienced as excessive and difficult to control and results in fatigue,
poor sleep and feeling on edge much of the time.

TABLE 2. 12-MONTH PREVALENCE OF ANXIETY DISORDERS IN AUSTRALIA AND
NEW ZEALAND8,9
Australia

New Zealand

Panic disorder

2.6%

1.7%

Social anxiety disorder (SAD)

4.7%

5.1%

Generalised anxiety disorder (GAD)

2.7%

2%

Any anxiety disorder (including PTSD and OCD)*

14.4%

14.8%

Agoraphobia without panic

2.8%

0.6%

Abbreviations: OCD = obsessive-compulsive disorder; PTSD = post-traumatic stress disorder.
* OCD and PTSD have since been moved out of the DSM-5 chapter on anxiety disorders and placed in their own
categories of ‘Obsessive compulsive and related disorders’, and ‘Trauma and stressor-related disorders’, respectively.

TABLE 3. MEAN AGE OF ONSET OF ANXIETY DISORDERS8,9
Australia

New Zealand

Panic disorder

30 years

24 years

Social anxiety disorder (SAD)

13 years

12 years

Generalised anxiety disorder (GAD)

33 years

32 years

Agoraphobia without panic

22 years

No available data

Substance use and misuse (including
over-the-counter medications, herbal medications and intoxication) or withdrawal
are often missed as a cause of anxiety, hence
it is important to screen for these.

Prevalence, cost and functional
impact
Anxiety disorders, as conceptualised in
previous classification systems such as
DSM-IV (that included OCD and PTSD
as anxiety disorders), form the most
14 MedicineToday

c ommon class of mental disorders.3-6 The
second A
 ustralian Survey of Mental Health
and Wellbeing, based on the DSM-IV,
estimated that one in seven adults (14.4%
of the population) experienced an anxiety
disorder in the past 12 months. A very
similar rate (14.8%) was estimated in New
Zealand.7,8 SAD is the most prevalent anxiety disorder, followed by GAD and panic
disorder/agoraphobia (Table 2).8,9 Anxiety
disorders are more common in women
than men; in people who are separated,

divorced or widowed; and those who are
less educated or unemployed. Demographic status may be both a consequence
and a cause of anxiety disorders.10
Anxiety disorders are associated with
high levels of distress, disability and service use.10 In the second Australian Survey
of Mental Health and Wellbeing, in people
who met criteria for an anxiety disorder,
about half reported an inability to work
or do normal tasks for less than one day
during the previous month because of
anxiety, a third reported one to seven days
and one-sixth reported more than seven
days.

Onset and course
Anxiety disorders typically start early in
life (Table 3), and prevalence declines with
age.7,11 Developing an anxiety disorder
after the age of 40 years is uncommon,
and so when a person over 40 presents
with an initial onset of an anxiety disorder,
alternative causes of anxiety such as mood
disorders, alcohol and substance use
disorders, trauma, physical illness or its
treatment should be considered.9,10
Panic disorder often follows a waxing
and waning course with periods of
increased anxiety (characterised by worsening or episodic flares of symptoms) and
periods of remission in between. Some
experience a fluctuating course with exacerbations that are often precipitated by
life-event stress, excess caffeine, sleep
disruption, physical illness or hormonal
changes, whereas others have a more
chronic course. Only a minority have
complete, sustained remission without
relapse.12-14
SAD is usually a chronic disorder.
Periods of remission are most common
in milder, nongeneralised SAD, in
nonclinical patients, and in those with
fewer social fears.15-17 The US National
Comorbidity Survey Replication estimates
that only 20 to 40% of people with SAD
recover within 20 years of onset and only
40 to 60% recover within 40 years.16
GAD is a chronic disorder that can be
exacerbated by stressful life events. Most
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TABLE 4. PATTERN AND OUTCOME OF ANXIETY DISORDERS

Panic disorder

1. WHEN TO SUSPECT OR LOOK FOR
AN ANXIETY DISORDER

Pattern of disorder

Outcome

• Chronic course OR a waxing
and waning course

• Only a small minority have
complete, sustained remission
without relapse

• Remission of symptoms in
between episodic flares
• Often precipitated by life event
stress
Social anxiety
disorder (SAD)

Generalised
anxiety
disorder (GAD)

• Chronic
• Periods of remission in milder
cases, nongeneralised SAD
and those with fewer social
fears
• Chronic disorder exacerbated
by stressful life events

patients are still affected after 10 years,
and half of those who remit will relapse
(Table 4).18,19

Service use
It is estimated that less than half of people
with anxiety disorders seek treatment
from a health professional. Those who do
seek treatment commonly attend primary
care, where anxiety is largely under-recognised.20 Only 30 to 60% of people who
see their GP for an anxiety disorder receive
a treatment regarded as adequate9,21 and
Australian data suggest that overall, only
a third of treatment-seekers receive minimally adequate treatment, with the rest
receiving counselling or inadequate
advice.22,23
People with panic disorder seek help
more frequently, often from medical specialists or emergency departments, probably because of concerns about their
physical symptoms.24-27 They are sometimes referred for unnecessary investigations to rule out possible medical
causes for the symptoms.
Comorbidity
There are high rates of comorbidity
between anxiety disorders and depressive
disorders. Most patients seen in a clinical
psychiatric practice will meet criteria for

• 20 to 40% recover within
20 years
• 40 to 60% recover within
40 years
• Most patients are still affected
after 10 years, and half of those
who remit will relapse

more than one mental disorder, and this
comorbidity is associated with most disability days and consultations due to mental disorders.28-30 Comorbidity should be
routinely assessed, as it is an indicator of
increased functional impairment and
economic costs.29,31-33
Comorbidity has been associated with
a slower rate of recovery and a poorer
response during active treatment. However, the presence of comorbidity should
not lead to undue pessimism about the
value of treatment and prospects for
eventual recovery, since both anti
depressant medication and CBT may still
be effective.34,35
Overall, medical comorbidity across
anxiety disorders is not associated with
poorer outcomes;36 and several studies
have shown that people with or without
comorbid disorders respond similarly to
face-to-face CBT and digitally-delivered
CBT (dCBT).37-39

Suicide risk
People with anxiety disorders have an
increased risk of suicidal ideation and
attempts, especially when comorbid with
depression. All patients with anxiety
disorders should be assessed for suicidal
thinking, risk of self-harm and the presence
of comorbid depression.

Suspect that an anxiety-related
condition requiring further assessment
is present in the following patient
presentations:
• unusually persistent anxiety for at
least six months, together with a
reported sense of urgency, impending
doom, apprehension, nervousness,
or feeling on edge. Also, patients
may report accompanying feelings of
restlessness, irritability, fatigue or
tension
• inability to stop or control worrying
thoughts for more than half the days
of the past six months
• excessive shyness, sensitivity, social
withdrawal or embarrassment beyond
that expected in this setting of
visiting the GP
• occurrence of a panic attack – an
abrupt surge of intense fear or
discomfort that reaches a peak within
minutes. The person often feels that
they must do something urgently
(e.g. escape to a safer place)
• medically unexplained symptoms
such as chest pain, rapid heart rate,
sweats or tremor
• panic symptoms, which may occur
across different types of anxiety
disorders such as social phobia,
specific phobia or trauma. They may
also arise in association with a
known or unrecognised medical
condition, hence the importance of
screening for medical disorders
(see Box 3)

Assessing patients presenting
with an anxiety disorder
When a patient presents with a suspected
anxiety disorder (Box 1), a comprehensive
assessment to obtain as much relevant
information as possible is essential to
providing an optimal treatment plan
(Box 2). The aims of the assessment are to:
• establish a good therapeutic
relationship with the patient
• develop a detailed biopsychosocial
and lifestyle formulation
• consider differential diagnoses and
establish a primary diagnosis
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2. COMPREHENSIVE ASSESSMENT OF PATIENTS PRESENTING WITH AN
ANXIETY DISORDER
Comprehensive assessment
Obtain information about the following:
• the nature, severity and duration of symptoms, avoidance behaviours and use of
safety behaviours (i.e. behaviours that patients carry out during attacks of anxiety
in the belief that it will prevent the feared catastrophes)
• the degree of distress and functional impairment
• the presence of comorbid anxiety or mood disorders, personality disorders, substance
use (including tobacco, illicit substances, prescribed and over-the-counter medications
and other substances such as caffeine and energy drinks), and medical conditions
(See Box 3)
• personal and family history of mental health disorders, and personal history of
chronic health problems, domestic violence or sexual abuse
• experience of, and response to, past treatments, including therapeutic response
and adverse effects
• the quality of interpersonal relationships and social support networks, living
conditions, social isolation, employment status including work environment, and
immigration status
• safety, including suicide risk
• medical evaluation including system review and appropriate physical examination
and blood tests including, at a minimum, thyroid function tests, electrolytes, full
blood count and blood glucose level, ECG if there are cardiac symptoms or a
relevant family history (e.g. arrhythmias). Further investigations should be guided by
the patient’s presentation, such as unusual symptoms or onset after the age of
40 years.
More specific information to guide diagnosis and treatment planning
• the underlying threat or danger that the patient is expecting (what negative
outcome/s do they fear)
• physiological symptoms and beliefs about somatic symptoms (e.g. pounding heart
that the patient fears may herald a heart attack)
• behavioural and cognitive responses to anxiety (e.g. avoidance, worry, reassuranceseeking, safety behaviours) (see Table 5)
• precipitants (triggers) for anxiety and avoidance

• identify comorbid disorders that may
affect treatment and outcome and
assist treatment planning
• assess psychosocial and lifestyle
factors that could help or hinder the
recovery process
• assess the capacity of the patient to
benefit from self-help material
independent of the clinician
(for example, ask about digital
competence, possibly indicated by
social media and other online activity).
Most cases of anxiety disorder are likely
to be diagnosed by a GP, but in cases of
uncertainty, a second opinion from a psychiatrist or clinical psychologist may be
helpful.
16 MedicineToday

Differentiating anxiety disorders
One of the most important ways of differentiating between anxiety disorders is
to examine the associated cognitions.
People with panic disorder worry that
their panic will result in physical or mental
harm to themselves, people with SAD
worry that they will be judged negatively,
and those with GAD worry excessively
across a variety of contexts (Table 1).
Importantly, panic attacks can occur in
any anxiety disorder (including specific
phobias), whereas OCD and PTSD occur
when people are confronted by their feared
or triggering situation. Being anxious a
lot of the time is not synonymous with
GAD as there are specific concerns and

features that are required for a clinical
diagnosis of GAD. There is a range of
self-report measures that can assist with
symptom assessment and monitoring
(Box 4).40-59

Treatment
These guidelines recommend a pragmatic
approach to selecting therapy in collaboration with the patient, beginning with
psychoeducation and advice on lifestyle
factors, followed by specific treatment.
Selection of treatment should be
based on:
• evidence of efficacy
• patient preference
• accessibility
• cost
• tolerability
• safety
• consideration of symptom severity
and comorbidity.
If symptoms are mild, transient and
without associated impairment in social
and occupational function, patients may
not require treatment.60 In such cases,
reassurance, psychoeducation and review
may be the most appropriate approach.
If symptoms are impairing the patient’s
ability to function, recommended initial
treatment options include:
• CBT, delivered face-to-face or
digitally, using a smartphone, tablet
or computer (dCBT)
• medication with an SSRI (or an
SNRI if SSRIs are ineffective or not
tolerated), accompanied by
instructions for graded exposure to
anxiety triggers
• a combination of CBT and
medication.
The choice of treatment should be
made in collaboration with the patient,
taking into consideration patient preference and prior responses to treatment,
with one proviso: that people with severe
anxiety disorders or severe comorbid
major depression be advised to consider
a combination of antidepressant medication and CBT. When possible, the
patient’s family or significant others
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3. COMMON MEDICAL CONDITIONS
ASSOCIATED WITH PANIC ATTACKS
OR PANIC-LIKE SYMPTOMS
Substance-induced
• Intoxication (e.g. stimulants)
• Adverse effects of over-the-counter
medications (e.g. decongestants,
beta-adrenergic inhalers, stimulants)
• Effects of caffeine-related products
(e.g. coffee, energy drinks/
supplements)
• Withdrawal (e.g. alcohol,
benzodiazepines)
Medical conditions
More clinically relevant

TABLE 5. KEY COGNITIVE SYMPTOMS AND MEASURES TO AID IN DIAGNOSIS
Consider

Ask about

Self-report
measure*

Panic disorder

Concern about panic outcomes i.e. that the severity
of the anxiety will cause a heart attack, collapse,
loss of control or death

PDSS-SR

Social anxiety
disorder (SAD)

Concern about negative evaluation i.e. that they will
embarrass themselves, or that others will think badly
of them (use Mini-SPIN self-report measure to
screen; SPS and SIAS as symptom measures)

Mini-SPIN
SPS/SIAS

Generalised
anxiety disorder
(GAD)

Excessive and uncontrollable worry about everyday
things, and concern that if they do not attend to the
worries then the outcome will be bad

GAD-7 or
PSWQ-3

Specific phobia

Persistent and excessive fear of a particular object
or situation (e.g. animals, heights, enclosed spaces,
injections, seeing blood)

FSS-II

Obsessive
compulsive
disorder

Worries about harming someone, contamination,
blasphemy, sexually deviant behaviour and related
images, impulses, urges

OCI-ROK

Post-traumatic
stress disorder

Intrusive memories of a past trauma (nightmares,
flashbacks) that cause distress and avoidance of
situations that could trigger the memories

PCL-C

Separation
anxiety disorder

Concern about being separated from home or
attachment figure

ASA-27

Illness anxiety
disorder

Concern about having a serious physical illness

SHAI

• Hyperthyroidism and (less common)
hypothyroidism
• Cardiac arrhythmias
• Vestibular dysfunction
• Seizure disorders (e.g. complex
partial seizures)
• Hypoglycaemia
Less clinically relevant
• Hypoparathyroidism and
hyperparathyroidism
• Phaeochromocytoma
• Pulmonary embolus
• Electrolyte disturbance
• Cushing’s syndrome
• Menopause/oestrogen deficiency

should be involved in management
planning decisions and in supporting
the patient through their treatment.
Despite the frequent use of CBT and
pharmacotherapy for anxiety disorders
in clinical practice, there is currently
limited evidence to support routine use
of this combination.

Cognitive behavioural therapy
At the simplest level, CBT helps patients
recognise and change the dysfunctional
thoughts, emotions and behaviours that
are part of the fear and avoidance that
typify and maintain their disorder. CBT
is a skills-based approach that consists
of psychoeducation about the nature and
maintenance of anxiety, providing skills

Major depressive Low mood, anhedonia, past-oriented rumination
disorder (MDD)
(e.g. ‘Why did I allow that to happen?’) and MDD
symptoms (e.g. sadness, loss of interest, worthlessness)

Item 9 of
PHQ-9
indicates
suicide risk

* See Box 4 for a full list of self-report measures.

in identifying and challenging anxious
thoughts and repeated and graded exposure to feared or avoided stimuli (situations, sensations or thoughts).
CBT can be delivered face-to-face
(individual or group), digitally, or through
self-guided CBT books for patients (selfhelp books). Face-to-face delivery of CBT,
particularly individual therapy, has been
the most extensively studied with its efficacy supported by meta-analyses.61 CBT
has been manualised for therapists and
patients, and CBT manuals can be digitised.62-64 Benefiting from CBT, whether
face-to-face or online, requires the patient
to practise their skills regularly.

Face-to-face CBT is effective, especially when conducted by a trained clinical psychologist, and is as or more
acceptable than digital help or self-help
methods. However, it is much less accessible, and there is a risk of loss of fidelity,
that is, a risk that the treatment delivered
may not include all the elements of the
treatment package that research has
shown to be effective. Digital CBT and
self-help have fidelity and are more accessible and may be as effective but are not
acceptable for some.
Psychotherapy is generally less associated with side effects than pharmacotherapy. Pharmacotherapy can be
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4. SELF-REPORT MEASURES FOR
ASSESSMENT AND DIFFERENTIAL
DIAGNOSIS
ACQ: Agoraphobic Cognitions
Questionnaire40
ASA-27: Adult Separation Anxiety
Questionnaire41
ASI: Anxiety Sensitivity Index42
DCQ: Dysmorphic Concern
Questionnaire43
EDI-3SC: Eating Disorder Inventory-3
Symptom Checklist44
FSS-II Fear: Survey Schedule II45
GAD-7: Generalised Anxiety Disorder-746
MI: The Mobility Inventory for
Agoraphobia47
Mini-SPIN: Mini-Social Phobia Inventory48
OCI-R: Obsessive Compulsive Inventory
– Revised49
PAS: Panic and Agoraphobia Scale50
PCL-C: PTSD Checklist Civilian Form51
PDSS-SR: Panic Disorder Severity Scale52
PHQ-9: Patient Health Questionnaire-953
PSWQ-3: Penn State Worry
Questionnaire-354
SHAI: Short Health Anxiety Inventory55
SPS/SIAS: Social Phobia Scale/Social
Interaction Anxiety Scale56
PCL-5: PTSD Checklist Civilian Form for
DSM 557-59

associated with adherence problems, but
medications are usually accessible. The
direct financial costs to the patient are
highest with any face-to-face intervention, i.e. talking therapy or medication.
It is likely that some patients will only
respond to CBT and others only to antidepressants. Therefore, persisting with
either when there is no response may not
be beneficial, and switching to the alternative may be more productive.65-68

Medications
The advantages of pharmacotherapy are
that the recommended medications are
easily prescribed in primary care, they are
widely available at relatively low cost, and
18 MedicineToday

the quality of medicines is assured. Antidepressants, especially the SSRIs and, to
a lesser extent, the SNRIs, are the first-line
medications for panic disorder, SAD and
GAD based on evidence from placebocontrolled randomised controlled trials,
overall safety and low misuse potential.69,70
Pharmacotherapy for anxiety d
 isorders
should always be accompanied by instructions for graded exposure to feared
situations.

Antidepressants, especially
the SSRIs and, to a lesser extent,
the SNRIs, are the first-line
medications for panic disorder,
SAD and GAD
SSRI and SNRI antidepressants
For about half of the participants in clinical
trials of SSRIs or SNRIs, symptoms
improve to the point that they no longer
meet criteria for the disorder. Disability
decreases and quality of life improves.
Although the tolerability profiles of SSRIs
and SNRIs in patients with anxiety disorders are not fully established, systematic
reviews of studies in depressed patients
suggest that duloxetine and venlafaxine
may be less well tolerated than the
SSRIs.71,72 Overall, the evidence does not
indicate that any one of these medications
be preferred over another and selection
should be made based on previous success
with the individual patient, patient preference, and clinician familiarity with the
medication.
SSRI and SNRI antidepressants can
have adverse effects including initial
exacerbation of anxiety (particularly
where there is a history of panic attacks),
nausea, headache, sleep disruption and
sexual dysfunction. It is important to be
aware that people with anxiety disorders,
particularly those with panic disorder,
are very aware of and concerned about
bodily symptoms. They should receive
careful education about likely adverse
effects if prescribed SSRI and SNRI

antidepressants and be warned that
adverse side effects usually occur early
in treatment before benefits are seen, and
these side effects usually settle. In
younger people, there has been an association of SSRIs with suicidal thoughts,
but not completed s uicide.73,74 Clinicians
should therefore use caution in prescribing any antidepressant in childhood or
early adolescence.
Dosing of SSRIs and SNRIs
To reduce the likelihood and severity of
side effects, and the risk of exacerbating
anxiety, it is advisable to start treatment
with antidepressants at a low dose (about
half of the starting dose given to depressed
patients) and to titrate slowly, increasing
the dose as tolerated to therapeutic effect.
Patients should be advised to take the
medication daily as prescribed, not just
when they feel anxious, and that it can
take up to six weeks to feel a benefit from
the medication, or even up to 12 weeks to
experience the full benefit.
There is inconsistent evidence for a
dose-response relationship; however,
some patients who have not responded
to a lower dose may respond to a higher
dose within the therapeutic dose range.
Little evidence is available to guide the
duration of treatment. If the desired
response is achieved, the medication
should be continued for 12 months. Discontinuation should be gradual, for
example, over three to four months to
minimise discontinuation symptoms or
withdrawal syndrome.
Other antidepressant classes
Tricyclic antidepressants (TCAs) have
demonstrated efficacy in the treatment
of panic disorder and GAD, but they are
associated with more side effects, poorer
tolerability and toxicity in overdose.
TCAs should be reserved for patients
who have not responded to, or are unable
to tolerate, SSRIs and SNRIs. Abrupt
discontinuation of TCAs may cause similar symptoms as well as lead to cholinergic rebound.75
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The irreversible monoamine oxidase
inhibitors (MAOIs) have proven efficacy
in SAD and panic disorder. However, their
use in the treatment of these disorders has
been limited because of serious potential
adverse effects, the need for dietary restrictions, toxicity in overdose and important
pharmacokinetic interactions; referral to
a psychiatrist to prescribe MAOIs is
advisable.
Moclobemide, a reversible inhibitor of
monoamine oxidase A (RIMA), has been
shown to be modestly effective in the
treatment of SAD, and there is limited
evidence that it is effective in the treatment
of panic disorder. Doses of RIMA up to
the recommended maximum dose do not
require dietary restriction. Above this
dose, dietary restrictions will be necessary
for foods containing tyramine.

Very few studies have evaluated mirtazapine in the treatment of anxiety disorders, but it is used by some clinicians.
There is some evidence to support the use
of agomelatine in GAD, but not the other
anxiety disorders.76
Drug-drug interactions with
antidepressants
Interactions with other drugs can occur
because of pharmacokinetic or pharmacodynamic effects. Prescribers are strongly
advised to check for the risk of interactions
when prescribing for a patient who is taking other medications.77
Stopping and switching
antidepressants
When ceasing some SSRIs and SNRIs
(especially paroxetine and venlafaxine),

many individuals experience a withdrawal syndrome, with flu-like symptoms, shock-like sensations, dizziness,
insomnia, vivid dreams, irritability and
crying spells, as well as excessive sweating
and myalgia. Fluoxetine and its metabolite have a very long half-life, which
means that discontinuation symptoms
are unlikely, but this also means that a
washout period of five weeks is required
before changing to another antidepressant or other medication.
Benzodiazepines
Benzodiazepines have well established
anxiolytic effects, but there is concern
about their use because of adverse effects,
(including cognitive impairment, falls,
and sedation) tolerance and dependence.78
Their use can undermine the effectiveness
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If a patient presents with acute anxiety,
it is important to:
• establish if the patient is posing
a threat to themselves or others
• establish if a psychiatric consultation
is required as a matter of urgency
• ideally, assess the patient in a calm,
safe environment with their consent,
and introduce social support from
appropriately informed family or
friends present
• assist as above with appropriate
professional staff present
(mental health worker or nurse)
Initial management and containment
of risk for first presentation patients
with acute severe anxiety requires the
GP to listen to the patient’s concerns.
These include:
• careful history taking to establish a
time course and any/all relevant
factors
• providing an appropriate explanation
to the patient of their condition and
the proposed management
• initiating behavioural management of
their symptoms
• teaching slow-breathing exercises if
the patient is hyperventilating
• providing a fast-acting anxiolytic
agent if necessary
• admission to a facility for inpatient
care in cases where the patient is
suicidal or when the anxiety cannot
be contained for a patient with
limited supports
• outpatient care with a responsible
adult
• appropriate monitoring, review and
follow up

of CBT by becoming a safety behaviour
when patients see taking a benzodiazepine
as their main source of relief. Such a belief
may present a barrier to considering other
means of managing their anxiety in
patients with panic disorder and SAD.
Because of these concerns, benzodiazepines should not be used as first-line
agents, but be reserved for patients whose
20 MedicineToday

symptoms have not responded to other
treatments. There is also potential for
abuse of benzodiazepines and, although
it is difficult to predict which patients will
develop long-term problems, benzodiazepines should be avoided in those with a
previous or current history of substance
abuse.79
Benzodiazepines may have a favourable safety profile in the management of
treatment-refractory anxiety disorders,
compared with atypical antipsychotic
agents.
Benzodiazepines are not recommended
routinely when commencing patients on
SSRIs – slow titration and frequent review
in the early stages of treatment will enable
most patients to start SSRIs without significant worsening of their anxiety.

An increase in alertness
and anxiety facilitates
problem-solving, whereas severe
anxiety impairs the ability
to problem-solve and can be
debilitating

Follow-up and monitoring
The onset of beneficial effects typically
occurs 4 to 6 weeks after starting treatment with either CBT or medication. GPs
should initially see the patient weekly to
monitor adherence and adverse effects, to
identify any exacerbation of symptoms
until there is a response and symptoms
have stabilised, and to listen to any concerns or anxieties the patient has regarding
treatment (the latter builds and strengthens the connection with the patient that
in turn will enhance the efficacy of treatment). The effectiveness of treatment
should be reviewed after four to six
sessions of weekly CBT or after four to
six weeks of pharmacotherapy with advice
on graded exposure to feared situations.
Rating scales (Box 4 and Table 5) can be
used to monitor change and are often
helpful for both patients and GPs.

Optimal arousal
and performance

Strong
Performance

5. MANAGEMENT OF PATIENTS
EXHIBITING SIGNIFICANT DISTRESS
FROM ACUTE ANXIETY

Increasing
attention
and interest

Impaired performance
because of strong anxiety

Weak
Low

Arousal

High

Figure. The Hebbian version of the YerkesDodson Law demonstrating the relationship
between anxiety and performance.
Adapted from Yerkes RM, Dodson JD (1908) and
Hebb DO. (1955).80,81

Education
All patients should be educated about
anxiety, especially the adaptive aspects; an
increase in alertness and anxiety facilitates
problem-solving, whereas severe anxiety
impairs the ability to problem-solve and
can be debilitating (Yerkes-Dodson curve;
Figure).80,81 This information is extremely
beneficial because the patient often feels
that what they have been experiencing is
frightening and unique to them. Education
about managing anxiety involves outlining
fear-reinforcement cycles to the patient
as an explanation for why anxiety has
persisted and the need to eventually confront what is feared.
Educating patients also includes the
promotion of healthy lifestyle behaviours
including healthy eating, good sleep, regular exercise and reduced use of caffeine,
tobacco and alcohol. Reliable, plainlanguage information for patients is available online (www.yourhealthinmind.org).
What can GPs do to help
someone who is acutely
anxious?
In patients experiencing acute anxiety, just
sitting in the waiting room often helps to
reduce symptoms because they know that
a doctor is near. However, if they are hyperventilating severely and do not respond to
reassurance, they can be guided through
a slow-breathing technique, in which they
are instructed to take light (not deep)
breaths in and out over cycles of about
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Online resources
The Black Dog Institute maintains a list of
organisations that provide online resources
for wellbeing and common mental disorders
(www.emhprac.org.au/services). Some 80
organisations offer a wide range of services.
Three of the organisations listed have
replicated randomised controlled trials
establishing the efficacy of their services
concerning the disorders covered in the
clinical practice guidelines1:
• Mental Health Online
(www.mentalhealthonline.org.au)
for panic disorder

Digital cognitive behavioural therapy
programs
Digital cognitive behavioural therapy
(dCBT) programs that are effective
in practice for people with mixed or
comorbid anxiety and depressive
disorders are available at:
• Mind Spot
(https://mindspot.org.au)
• This Way Up
(https://thiswayup.org.au)
These websites are preferred when
recommending dCBT.

• MoodGYM
(https://moodgym.com.au)
for generalised anxiety disorder (GAD)
• This Way Up
(https://thiswayup.org.au) for panic
disorder, social anxiety disorder and GAD

six-seconds. It is likely to take at least five
minutes of this to have an effect, and if the
patient becomes distressed again during
the consultation it can be repeated. The
management of significant distress from
acute anxiety, as marked by extreme and
severe symptoms, is outlined in Box 5.
Patients suffering from chronic anxiety
require a more comprehensive management approach. It is important to remember that anxiety often fluctuates, and GPs
will almost certainly be seeing the patient
at their worst. Resist the urge to write a
prescription immediately, as many people
are instantly reassured just by knowing
from the GP that they have a recognisable
and treatable condition.
There are also a number of online
resources that GPs can refer patients to.
These are listed in Box 6.

Managing the doctor’s anxiety
As with all illnesses, patients with anxiety
disorders visit their GP when their symptoms are severe. The GP may interpret
this high level of anxiety as an urgent need
to do something. A GP’s anxiety can lead
them to prescribe sedating m
 edication
(including sedating antidepressants,
22 MedicineToday

a ntipsychotics, benzodiazepines or
antihistamines) or overinvestigate for all
possible differential diagnoses. Our anxiety as doctors comes from our uncertainty about being able to relieve a patient’s
distress, a mistaken sense that this needs
to be done urgently and excessive concern
not to miss a physical cause of anxiety.
Unless the patient is expressing urgent
suicidal ideation and intent, anxiety or
even an acute panic attack does not cause
serious harm. It is important for GPs to
manage their anxiety about the patient’s
anxiety. Patients frequently feel reassured
when a diagnosis and treatment plan are
provided.

Conclusion
Anxiety disorders are common in adults,
but often missed and poorly treated in
clinical practice. The RANZCP Clinical
Practice Guidelines for anxiety disorders
provide updated and relevant information
for clinicians regarding the management
of anxiety disorders. We have drawn from
the guidelines to provide GPs with practical clinical tools to help manage patients
with panic disorder, SAD and GAD. The
full guidelines concern the acute,

continuation and maintenance phases of
treatment, and provide clear guidance to
ensure the optimal management of patients
with anxiety disorders. The advice provided in the clinical practice guidelines
should equip GPs to navigate the complexities of managing these conditions.  MT
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